on NFL BIOSCIENCES (EPA:ALNFL)
NFL Biosciences Confirms NFL-101's Efficacy in Tobacco Addiction Treatment
NFL Biosciences, a biopharmaceutical company, announces the results from the Phase 2 CESTO II study, highlighting the efficacy of NFL-101 for tobacco addiction. This first-in-class treatment induces a dose-dependent increase in anti-tobacco immunoglobulin (IgG) levels, which correlates with continuous smoking abstinence.
The study reveals that NFL-101 generates a unique biological response, not observed in the placebo group. This response is marked by higher IgG levels in individuals achieving continuous abstinence, signifying a strong association between NFL-101 and sustained tobacco abstinence.
The company's CEO, Bruno Lafont, underscores the clinical findings, stating that NFL-101 is positioned as a natural, safe, and effective alternative to existing tobacco cessation methods, promoting discussions with regulatory bodies for future Phase 3 trials.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all NFL BIOSCIENCES news